AI Engines For more Details: Perplexity Kagi Labs You
Antiandrogenic Activity: Cyproterone acetate is known for its antiandrogenic properties, meaning it inhibits the effects of androgens (male hormones) in the body. It competitively blocks the androgen receptor, preventing the binding of testosterone and dihydrotestosterone (DHT) to their receptors. This action reduces the effects of androgens on target tissues and can be beneficial in the treatment of conditions characterized by androgen excess.
Treatment of Hirsutism: Cyproterone acetate is used in the treatment of hirsutism, a condition characterized by excessive hair growth in women, typically in a male-pattern distribution (such as on the face, chest, and back). By blocking androgen receptors and reducing the effects of circulating androgens, cyproterone acetate can help slow down the growth of unwanted facial and body hair in women with hirsutism.
Treatment of Acne: Cyproterone acetate is also used in the treatment of acne vulgaris, particularly in women with hormonal acne or acne that is resistant to conventional therapies. By inhibiting androgen activity, cyproterone acetate helps reduce sebum production, which is a key factor in the development of acne lesions. It is often combined with estrogen-containing oral contraceptives in the treatment of acne to achieve optimal results.
Androgenetic Alopecia: Cyproterone acetate may be used off-label in the treatment of androgenetic alopecia (male-pattern baldness) in women, particularly in cases where excessive androgen levels contribute to hair loss. By blocking androgen receptors and reducing the effects of androgens on hair follicles, cyproterone acetate may help slow down or stabilize hair loss and promote hair regrowth in some individuals.
Treatment of Hyperandrogenism: Cyproterone acetate is also used in the treatment of hyperandrogenism, a condition characterized by elevated levels of androgens in the body. It may be used to manage symptoms associated with conditions such as polycystic ovary syndrome (PCOS), congenital adrenal hyperplasia (CAH), and androgen-secreting tumors. By reducing androgen levels and inhibiting androgen activity, cyproterone acetate helps alleviate symptoms such as hirsutism, acne, and menstrual irregularities associated with hyperandrogenism.
Contraception: In some countries, cyproterone acetate is combined with ethinyl estradiol (a synthetic estrogen) in oral contraceptive pills for birth control purposes. These combination pills provide both contraceptive and antiandrogenic effects, making them useful for women with androgen-related conditions such as hirsutism, acne, or polycystic ovary syndrome (PCOS).
Side Effects: Common side effects of cyproterone acetate may include menstrual irregularities, breast tenderness, nausea, fatigue, and mood changes. Long-term use of cyproterone acetate may be associated with an increased risk of liver toxicity, thromboembolic events (such as blood clots), and depression. Patients should be monitored regularly for side effects during cyproterone acetate therapy, and treatment should be adjusted as needed based on individual response and tolerance.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.7 | 0.4 | 0.75 |
| Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.3 | 0 |
| Allergic Rhinitis (Hay Fever) | 1.1 | 1.1 | |
| Allergies | 0.3 | 0.9 | -2 |
| Allergy to milk products | 0.3 | 0.3 | 0 |
| Alopecia (Hair Loss) | 0.8 | 0.8 | |
| Alzheimer's disease | 0.8 | 1 | -0.25 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 0.1 | 5 |
| Ankylosing spondylitis | 2 | 0.9 | 1.22 |
| Anorexia Nervosa | 0.3 | 0.5 | -0.67 |
| Antiphospholipid syndrome (APS) | 1.3 | 1.3 | |
| Asthma | 0.5 | -0.5 | |
| Atherosclerosis | 0.1 | 1 | -9 |
| Atrial fibrillation | 0.8 | 1.3 | -0.63 |
| Autism | 3.6 | 3 | 0.2 |
| Barrett esophagus cancer | 0.1 | 0.1 | 0 |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Bipolar Disorder | 0.5 | 0.7 | -0.4 |
| Brain Trauma | 0.5 | -0.5 | |
| Carcinoma | 0.5 | 0.4 | 0.25 |
| Celiac Disease | 1 | 0.4 | 1.5 |
| Cerebral Palsy | 0.1 | 0.5 | -4 |
| Chronic Fatigue Syndrome | 1.2 | 3.1 | -1.58 |
| Chronic Kidney Disease | 1.1 | 0.7 | 0.57 |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | 0.7 | -0.4 |
| Chronic Urticaria (Hives) | 0.3 | 1.1 | -2.67 |
| Coagulation / Micro clot triggering bacteria | 0.6 | 0.4 | 0.5 |
| Colorectal Cancer | 1.7 | 1.7 | |
| Constipation | 0.9 | 0.3 | 2 |
| Coronary artery disease | 0.6 | 0.4 | 0.5 |
| COVID-19 | 1.5 | 3.8 | -1.53 |
| Crohn's Disease | 2.5 | 1.4 | 0.79 |
| cystic fibrosis | 0.2 | 0.5 | -1.5 |
| deep vein thrombosis | 0.2 | 0.4 | -1 |
| Depression | 3 | 2.7 | 0.11 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.7 | 0.5 | 0.4 |
| Endometriosis | 1 | 1 | |
| Eosinophilic Esophagitis | 0.1 | 0.1 | |
| Epilepsy | 0.6 | 0.7 | -0.17 |
| Fibromyalgia | 0.9 | 1.7 | -0.89 |
| Functional constipation / chronic idiopathic constipation | 2.1 | 2 | 0.05 |
| gallstone disease (gsd) | 0.3 | 0.5 | -0.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | 0.1 | 9 |
| Generalized anxiety disorder | 1 | 0.5 | 1 |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.4 | -0.4 | |
| Graves' disease | 0.4 | 0.3 | 0.33 |
| Halitosis | 0.2 | 0.1 | 1 |
| Hashimoto's thyroiditis | 0.5 | 0.1 | 4 |
| Hidradenitis Suppurativa | 0.2 | 0.2 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.9 | 0.3 | 2 |
| hyperglycemia | 0.1 | 0.4 | -3 |
| hypertension (High Blood Pressure | 0.5 | 1.1 | -1.2 |
| Hypothyroidism | 0.4 | -0.4 | |
| Hypoxia | 0.4 | 0.4 | |
| IgA nephropathy (IgAN) | 1.9 | -1.9 | |
| Inflammatory Bowel Disease | 1.4 | 3.4 | -1.43 |
| Insomnia | 0.2 | 0.5 | -1.5 |
| Intelligence | 0.4 | 0.9 | -1.25 |
| Intracranial aneurysms | 0.4 | 0.4 | |
| Irritable Bowel Syndrome | 1.2 | 1.4 | -0.17 |
| Liver Cirrhosis | 1.4 | 0.9 | 0.56 |
| Long COVID | 3.2 | 1.6 | 1 |
| Low bone mineral density | 0.7 | -0.7 | |
| Lung Cancer | 0.1 | 0.1 | |
| ME/CFS with IBS | 0.1 | 0.8 | -7 |
| ME/CFS without IBS | 0.8 | 1 | -0.25 |
| Metabolic Syndrome | 2.4 | 2.2 | 0.09 |
| Mood Disorders | 3.4 | 2.7 | 0.26 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 0.8 | 2.7 | -2.38 |
| Multiple system atrophy (MSA) | 0.1 | 0.1 | |
| Neuropathy (all types) | 0.1 | 0.1 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1 | 0.5 | 1 |
| Obesity | 2 | 1.5 | 0.33 |
| obsessive-compulsive disorder | 1.6 | 2 | -0.25 |
| Osteoarthritis | 0.9 | 0.9 | |
| Osteoporosis | 0.2 | 0.1 | 1 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 0.9 | 1.8 | -1 |
| Polycystic ovary syndrome | 1.1 | 0.3 | 2.67 |
| Postural orthostatic tachycardia syndrome | 0.4 | -0.4 | |
| Premenstrual dysphoric disorder | 0.3 | -0.3 | |
| Psoriasis | 0.4 | 2.8 | -6 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3 | 1.1 | 1.73 |
| Rosacea | 0.3 | -0.3 | |
| Schizophrenia | 0.8 | 0.7 | 0.14 |
| scoliosis | 0.4 | 0.4 | |
| Sjögren syndrome | 1.3 | 0.4 | 2.25 |
| Sleep Apnea | 0.5 | 0.8 | -0.6 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 1 | 0.8 | 0.25 |
| Systemic Lupus Erythematosus | 1.9 | 0.3 | 5.33 |
| Tic Disorder | 0.7 | 0.9 | -0.29 |
| Tourette syndrome | 0.1 | -0.1 | |
| Type 1 Diabetes | 1.4 | 1.1 | 0.27 |
| Type 2 Diabetes | 3.1 | 2.7 | 0.15 |
| Ulcerative colitis | 0.6 | 2.6 | -3.33 |
| Unhealthy Ageing | 2.5 | 0.7 | 2.57 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.